In the following video, Motley Fool health-care bureau chief Brenton Flynn takes a look at two different companies with drugs facing FDA approval decisions in February. He discusses ImmunoGen (IMGN) and its drug T-DM1, where approval is already expected by the market, as well as Dynavax (DVAX 0.17%) and its hepatitis B vaccine Heplisav. Dynavax is the wildcard of this group, and Brenton gives his prediction for whether or not the drug will be approved.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.